The FDA recently approved Cobenfy, the first schizophrenia treatment with a novel mechanism of action in decades. This oral combination of xanomeline (M1/M4 muscarinic acetylcholine receptors (mAChRs) agonist) and trospium chloride (peripherally restricted pan-mAChR antagonist) selectively activates M1/M4 receptors in the brain, avoiding peripheral side effects.
Chemspace offers a carefully selected set of Biologics for studying the M1 mAChR (https://chem-space.com/biologics/list/3f36386bf5124170a0ddf549d7179026), with M4 mAChR Biologics coming soon.
M1 mAChR in humans is encoded by the CHRM1 gene, which is primarily expressed in the central nervous system (CNS) and plays a critical role in cognitive function, memory formation, and motor control. Dysregulation of CHRM1 is implicated in Alzheimer’s disease, Parkinson’s disease, schizophrenia, and other CNS disorders, making it a valuable therapeutic target.
Our set enables researchers to identify and localize CHRM1 in experimental models accurately, explore receptor function and signaling pathways, and conduct neuroscience studies.
If you are interested in M1 mAChR or other targets or wish to explore our biological services, contact us at [email protected]. We’re here to support your research journey.